

Gabapentin Receptor $\alpha 2\delta$ -1 Is a Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis

Çagla Eroglu,^{1,2,*} Nicola J. Allen,² Michael W. Susman,² Nancy A. O'Rourke,³ Chan Young Park,² Engin Özkan,^{3,4} Chandrani Chakraborty,² Sara B. Mulinyawe,² Douglas S. Annis,⁵ Andrew D. Huberman,² Eric M. Green,² Jack Lawler,⁸ Ricardo Dolmetsch,² K. Christopher Garcia,^{3,4} Stephen J. Smith,³ Z. David Luo,^{6,7} Arnon Rosenthal,⁹ Deane F. Mosher,⁵ and Ben A. Barres²

¹Duke University Medical Center, Cell Biology Department, Durham, NC 27710, USA

²Department of Neurobiology

³Department of Molecular and Cellular Physiology

⁴Department of Structural Biology, Howard Hughes Medical Institute
Stanford University School of Medicine, Stanford, CA 94305-5125, USA

⁵Department of Medicine, Medical Sciences Center, University of Wisconsin, Madison, WI 53706, USA

⁶Department of Anesthesiology and Perioperative Care

⁷Department of Pharmacology

University of California Irvine Medical Center, Orange, CA 92868, USA

⁸Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

⁹MazoRx Inc., P.O. Box 610098, Redwood City, CA 94061, USA

*Correspondence: c.eroglu@cellbio.duke.edu

DOI 10.1016/j.cell.2009.09.025

SUMMARY

Synapses are asymmetric cellular adhesions that are critical for nervous system development and function, but the mechanisms that induce their formation are not well understood. We have previously identified thrombospondin as an astrocyte-secreted protein that promotes central nervous system (CNS) synaptogenesis. Here, we identify the neuronal thrombospondin receptor involved in CNS synapse formation as $\alpha 2\delta$ -1, the receptor for the anti-epileptic and analgesic drug gabapentin. We show that the VWF-A domain of $\alpha 2\delta$ -1 interacts with the epidermal growth factor-like repeats common to all thrombospondins. $\alpha 2\delta$ -1 overexpression increases synaptogenesis in vitro and in vivo and is required postsynaptically for thrombospondin- and astrocyte-induced synapse formation in vitro. Gabapentin antagonizes thrombospondin binding to $\alpha 2\delta$ -1 and powerfully inhibits excitatory synapse formation in vitro and in vivo. These findings identify $\alpha 2\delta$ -1 as a receptor involved in excitatory synapse formation and suggest that gabapentin may function therapeutically by blocking new synapse formation.

INTRODUCTION

Central nervous system (CNS) synapses are complex cell-cell adhesions between neurons. Their establishment requires an interaction between axons and dendrites, accompanied by the

appositional organization of pre- and postsynaptic specializations. Several neuronal cell surface molecules and secreted signals have been shown to be involved in processes that lead to synaptic organization and maturation (Fox and Umemori, 2006), but molecules that regulate the formation of initial synaptic adhesions remain poorly understood. Accumulating evidence from our lab and others has shown that astrocytes play active roles in the formation of synapses (Eroglu et al., 2008). We have previously identified thrombospondins (TSP) as a necessary and sufficient synaptogenic signal secreted by astrocytes that increases synapse number (Christopherson et al., 2005). TSP is present in astrocyte-conditioned media (ACM) and is responsible for the ability of astrocytes to increase synapse number in vitro (Christopherson et al., 2005). TSPs are also important for synapse formation in vivo. *TSP1/2*-deficient mice have a significant decrease in the number of excitatory synapses. TSP1 and 2 are expressed during early postnatal ages, when the majority of synapses are forming, and these proteins are absent from the adult brain when the amount of excitatory synaptogenesis is significantly reduced (Christopherson et al., 2005). Upon injury to the CNS, TSP1/2 levels are up-regulated, and lack of TSP1/2 impairs synaptic and functional recovery from stroke (Liauw et al., 2008).

TSP is able to promote synaptic adhesion and initiate the events that lead to the establishment of pre- and postsynaptic specializations. Interestingly, these TSP-induced synapses are ultrastructurally identical to fully developed synapses and are presynaptically active but postsynaptically silent because of the lack of surface AMPA receptors. Astrocytes secrete a second unrelated signal that is able to convert these silent synapses into fully active ones (Christopherson et al., 2005) (N.J.A. and B.A.B. unpublished data).

TSPs are large oligomeric, multidomain, extracellular matrix proteins that have been previously shown to play important roles in cell attachment, cell migration, cytoskeletal dynamics, and angiogenesis (Bornstein et al., 2004). TSP mediates these functions via its interaction with various cell surface receptors through specific domains (Adams and Lawler, 2004). We hypothesized that TSPs induce synapse formation by interacting with a neuronal cell-surface receptor. Here, we show that TSPs mediate synaptogenesis through their epidermal growth factor (EGF)-like domains, common to all TSP isoforms. Using this domain information, we identified the gabapentin receptor $\alpha 2\delta$ -1 as the TSP receptor involved in synapse formation.

$\alpha 2\delta$ -1 (Cacna2d1) was originally isolated as a nonessential subunit of the L-type calcium channel complex from skeletal muscle (Arikath and Campbell, 2003), and it also binds to other proteins (Kaltenbach et al., 2007). $\alpha 2\delta$ -1 is ubiquitously expressed in many tissues and is highly expressed by many CNS neurons (Cole et al., 2005), including retinal ganglion cells (RGCs). $\alpha 2\delta$ -1 is translated from a single gene product, which gets posttranslationally cleaved into $\alpha 2$ and δ parts that remain associated via disulfide bridges. The $\alpha 2$ part of the protein (~950 amino acids) is entirely extracellular, while the δ part has a small extracellular part that is attached to $\alpha 2$ and a transmembrane domain with a very short cytoplasmic tail that tethers the protein to the membrane (Davies et al., 2007).

Much research on $\alpha 2\delta$ -1 has focused on its role in the regulation of calcium channel function and trafficking. However, the presence of a large extracellular region containing a well-known protein-protein interaction fold, the Von Willebrand Factor A (VWF-A) domain, suggests that this protein could serve as a receptor for extracellular ligands. A recent study on skeletal muscle cells, which express high levels of $\alpha 2\delta$ -1, described such a role for $\alpha 2\delta$ -1 in myoblast attachment and extracellular signaling that is independent of calcium channel function (Garcia et al., 2007).

$\alpha 2\delta$ -1 is the high-affinity receptor for two commonly prescribed antiepileptic, antineuropathic pain medications, gabapentin (GBP, Neurontin) and pregabalin (Lyrica) (Gee et al., 1996). GBP and pregabalin were initially designed as hydrophobic gamma amino butyric acid (GABA) analogs that could cross the blood-brain barrier. Further studies have shown that even though they possess anticonvulsant properties, they do not bind to GABA receptors or transporters. A recent study using a knockin mouse that expresses a mutant $\alpha 2\delta$ -1 that cannot bind GBP or pregabalin has shown that $\alpha 2\delta$ -1 is the *in vivo* target for these drugs and that these drugs mediate their therapeutic action through binding to $\alpha 2\delta$ -1 (Field et al., 2006). GBP and pregabalin do not affect the single-channel kinetics of calcium channels and have only modest effects on neurotransmission (Dooley et al., 2007). Thus, the cellular mechanisms underlying the mode of action of these drugs are unclear.

In this study, we show that EGF-like domains of TSP directly bind to $\alpha 2\delta$ -1 and mediate its synapse-inducing activity via this receptor. These findings identify $\alpha 2\delta$ -1 as a neuronal TSP receptor that is required for CNS synapse formation. This function of $\alpha 2\delta$ -1 is likely to be independent of calcium channel function. We also show that GBP is a potent inhibitor of TSP/astrocyte-induced excitatory synapse formation *in vitro* and

in vivo. This function of GBP may be a central part of its mechanism of action.

RESULTS

All TSP Isoforms Induce Synapse Formation

There are five TSP isoforms in mammals, which fall into two groups according to their domain structure and oligomerization states (Figure 1A). Trimeric subgroup A TSPs, TSP1 and 2, are synaptogenic (Christopherson et al., 2005). To determine whether pentameric subgroup B TSPs are also synaptogenic, we cultured RGCs in the presence of astrocytes or with TSP 1, 3, 4, or 5. All subgroup B TSPs increased synapse number significantly to similar levels as TSP1 or astrocytes (Figures 1B–1D). These results suggest that the synaptogenic domain of TSP is located in the conserved C-terminal portion of TSP, which is common to all isoforms spanning the EGF-like repeats, the calcium-binding repeats, and C-terminal L-type lectin-like globular domain.

The Synaptogenic Activity of TSP Maps to Its EGF-like Repeats

TSPs interact with a number of known cell-surface receptors through specific domains (Adams and Lawler, 2004). To identify the synaptogenic domain of TSP, we treated RGCs with a panel of recombinant truncation constructs of TSP1 and 2. The TSP fragments that contained the EGF-like repeats mimicked the ability of full-length TSP to induce synapses (Figures 2B and 2C). A fragment containing the third EGF-like repeat together with the C-terminal region of TSP2 also significantly increased synapse number; however, the third EGF-like domain alone did not induce a significant increase in synapse number (Figure 2C).

We confirmed the importance of the EGF-like repeats in synapse formation by functionally blocking synaptogenic effect of TSP on cultured RGCs, using monoclonal antibodies directed against different epitopes of TSP (Figure 2D). Monoclonal antibodies against the second (HB8432 and C6.7) (Annis et al., 2007) or third EGF-like repeats (A4.1) (Annis et al., 2006) blocked the synaptogenic effect of TSP, whereas an antibody against the N-terminal domain (mAb200-1) did not (Figure 2E).

To aid us in our efforts to identify the neuronal TSP receptor involved in synapse formation, we expressed and purified a myc and 6-Histidine tagged TSP2 fragment containing all three EGF-like repeats (Figures S1A and S1B available online). This TSP2 fragment (designated SD2 for synaptogenic domain 2) was strongly synaptogenic (Figures S1C and S1D). Collectively, these data suggest that TSP-induced synapse formation is mediated by an interaction involving EGF-like repeats of TSP.

$\alpha 2\delta$ -1 Interacts with the Synaptogenic Domain of TSP

The EGF-like domains of TSP4 have been shown to bind to the VWF-A domain of integrin αM (Pluskota et al., 2005). Thus, we investigated whether integrin αM or other VWF-A domain containing integrins in RGCs were involved in TSP-induced synapse formation. None of the integrins that contained the VWF-A domain and were expressed by RGCs were crucial for the synaptogenic activity of TSP (data not shown).




Figure 1. All Thrombospondin Isoforms Are Synaptogenic

(A) TSPs are divided into two subgroups. The N-terminal domain (black), the procollagen repeat (red), and properdin-like repeats (orange), EGF-like repeats (blue), calcium binding repeats (gray), and C-terminal L-lectin like globular domain (green) are shown.

(B) Immunostaining of RGCs for synaptotagmin (red) and PSD-95 (green). White arrows point to colocalized synaptic puncta. The scale bar represents 30 μ m.

(C and D) Quantification of the effects of astrocytes, purified TSP1, 4, and 5 (8 nM each) (C) and conditioned media from COS7 cells overexpressing either TSP3 or empty vector (D) on synapse number. In all graphs, $n = 20$ cells. Error bars show the mean \pm SEM, * $p < 0.05$.

Beads conjugated to an anti FLAG-tag antibody were used to immunoprecipitate $\alpha 2\delta$ -1-FLAG. SD2 coimmunoprecipitated with $\alpha 2\delta$ -1-FLAG, but the Control-myc-his protein did not (Figure 3C, lanes 8 and 9, respectively), suggesting that $\alpha 2\delta$ -1 specifically interacts with the synaptogenic EGF-like domains of TSP.

We hypothesized that the EGF-like domains of TSP interact with the VWF-A domain of $\alpha 2\delta$ -1, which resides in the $\alpha 2$ region of the protein. So that this could be tested, three $\alpha 2\delta$ -1 constructs, the full-length $\alpha 2\delta$ -1, $\alpha 2$, or VWF-A domain, each with a C-terminal Protein C (PC) tag for purification (Figure 3D), were coexpressed with SD2. When we performed PC tag affinity purifications, we could detect SD2 in all three purified fractions (Figure 3E, lanes 7, 8, and 9). SD2 did not copurify with an unrelated membrane protein that also contained the same PC tag (Figure 3E, lane 6). These data show that TSP and $\alpha 2\delta$ -1 interact through

the synaptogenic EGF-like domains of TSP and the VWF-A domain of $\alpha 2\delta$ -1.

$\alpha 2\delta$ -1 Is the Neuronal TSP Receptor Involved in Synapse Formation

To determine whether $\alpha 2\delta$ -1 plays a role in TSP-induced synapse formation in vitro, we overexpressed $\alpha 2\delta$ -1 in RGCs and tested whether SD2-induced synapse formation was affected. RGCs that overexpressed $\alpha 2\delta$ -1 (identified with GFP coexpression) received twice as many synapses in response to SD2 as did RGCs transfected with empty vector (Figure 4A), indicating that $\alpha 2\delta$ -1 overexpression enhances TSP-induced synapse formation. $\alpha 2\delta$ -1 overexpression was not sufficient to induce synapse formation in the absence of SD2, suggesting that SD2 is required for the enhancement of synapse formation by $\alpha 2\delta$ -1.

To determine which region of the $\alpha 2\delta$ -1 protein was responsible for its enhancement of SD2-induced synapse formation, we utilized two $\alpha 2\delta$ -1 constructs (schemed in Figure 4A). Overexpression of a " $\alpha 2\delta$ -1Adh" construct that contains the entire extracellular region of $\alpha 2\delta$ -1 followed by the transmembrane domain from an unrelated type 1 membrane protein adhalin

Another class of cell-surface proteins that contains VWF-A domains is the alpha2 delta ($\alpha 2\delta$) family. Among the $\alpha 2\delta$ proteins cloned to date (Klugbauer et al., 2003), RGCs express high levels of $\alpha 2\delta$ -1 (Figure S2A). We investigated whether $\alpha 2\delta$ -1 is localized to synapses using array tomography (Micheva and Smith, 2007). Ultra-thin sections from rat cortex or mouse LGN were immunolabeled with antibodies against $\alpha 2\delta$ -1 and the pre- and postsynaptic markers synapsin and MAGUK. $\alpha 2\delta$ -1 gave a punctate staining pattern. Some $\alpha 2\delta$ -1 puncta localized to synapses identified as juxtapositioned pre- and postsynaptic puncta, while some colocalized exclusively with pre- or postsynaptic puncta (Figures 3A and S2B).

To determine whether $\alpha 2\delta$ -1 interacts with TSPs, we immunoprecipitated TSP1, 2, and 4 from P5 rat cerebral cortex lysate. $\alpha 2\delta$ -1 was detected in immunoprecipitation fractions performed with each of the three TSP antibodies (Figure 3B), suggesting that $\alpha 2\delta$ -1 and TSPs interact in vivo.

To test whether there is a direct and specific binding interaction between the synaptogenic domain of TSP and $\alpha 2\delta$ -1, we coexpressed a FLAG-tagged $\alpha 2\delta$ -1 alone (Figure 3C, lane 2), with SD2 (lane 4), or with an unrelated secreted control protein that contained an EGF-like repeat (Control-myc-his, lane 5).




Figure 2. EGF-like Repeats of TSPs Are Synaptogenic

(A) The domain structure of TSP1 and 2. N-terminal domain (black), oligomerization domain and a procollagen repeat (red, PC), three properdin-like (TSP type 1, orange, P1-P3), three EGF-like (TSP type 2, blue, E1-E3), and 13 calcium binding (TSP type 3, gray) repeats [Ca(wire)] and a C-terminal L-type lectin like globular domain (green, C).

(B and C) Quantification of the effect of TSP1 (B) and TSP2 (C) fragments on synapse number. RGCs were treated with astrocytes, full-length TSP1, or a panel of TSP1 or TSP2 fragments (8 nM each).

(D) Location of epitopes targeted by TSP blocking antibodies (modified from Carlson et al. [2008]). The inset shows a magnified structure of EGF-like repeats and the Ca-binding wire region and the C-terminal L-lectin like domain. Highlighted domains indicate putative synaptogenic domain of TSP.

(E) Quantification of the effect of monoclonal anti-TSP antibodies on TSP's synaptogenic activity. In all graphs, $n = 20$ cells. Error bars show the mean \pm SEM, * $p < 0.05$.

3B4 induced synapse formation similar to TSP. A control antibody (OX7) against another RGC surface receptor (Thy1) did not affect synapse formation. The synaptogenic effect of 5A5 or 3B4 was not additive with that of TSP (Figure 4B). These data show that antibody binding to the VWF-A domain can mimic TSPs synaptogenic function and suggest that the interaction of TSP with the VWF-A domain of $\alpha 2\delta -1$ is important for the initiation of synapse formation. Such ligand-mimicking antibodies were also described for VWF-A domain-containing integrins (Wilkins et al., 1996).

(Gurnett et al., 1996) mimicked the effect of full-length $\alpha 2\delta -1$ in enhancing SD2-induced synapse formation (Figure 4A), suggesting that the critical region of $\alpha 2\delta -1$ maps to the extracellular part of the protein. We next overexpressed a " $\delta -1$ only" construct (lacking the $\alpha 2$ region), which inhibited SD2-induced synapse formation (Figure 4A), indicating that the VWF-A-containing $\alpha 2$ region is necessary for enhancing synaptogenesis and that regions within $\delta -1$ may be involved in regulating downstream interactions that are critical for TSP-induced synapse formation.

Since the VWF-A domain of $\alpha 2\delta -1$ binds TSP, we investigated whether antibodies against the VWF-A domain of $\alpha 2\delta -1$ would interfere with TSP-induced synapse formation. Two monoclonal antibodies directed against the VWF-A domain of $\alpha 2\delta -1$, 5A5 and 3B4, recognized $\alpha 2\delta -1$ in western blots and stained the surface of HEK293 cells overexpressing $\alpha 2\delta -1$ (Figures S3A and S3B). When RGCs were cultured with these antibodies in the presence or absence of TSP and synapse number analyzed, both 5A5 and

To determine whether $\alpha 2\delta -1$ is required for TSP-induced synapse formation, we used a small interfering RNA (siRNA) knockdown approach. An siRNA pool specific for rat $\alpha 2\delta -1$ significantly reduced the expression of rat $\alpha 2\delta -1$ in transfected HEK293 cells (Figure 4C). Knockdown of $\alpha 2\delta -1$ in RGCs with this siRNA pool inhibited astrocyte or TSP-induced synapse formation in vitro (Figures 4D and 4E), whereas the nontargeting control siRNA pool (siControl) did not affect synapse formation (Figures 4C and 4D).

To show that the reduction in synapse formation by the $\alpha 2\delta -1$ siRNAs was due to the specific knockdown of $\alpha 2\delta -1$, we tested whether the siRNA inhibition could be rescued by coexpressing an siRNA resistant $\alpha 2\delta -1$ construct. One of the siRNAs against rat $\alpha 2\delta -1$, si $\alpha 2\delta -1$ Duplex 9, blocked overexpression of rat $\alpha 2\delta -1$ but not human $\alpha 2\delta -1$ in HEK293 cells (Figure S4). When we cotransfected RGCs with si $\alpha 2\delta -1$ (9) and the human $\alpha 2\delta -1$ construct, we rescued SD2 or astrocyte-induced synapse formation (Figure 4F), showing that siRNA knockdown of $\alpha 2\delta -1$




Figure 3. Thrombospondins Interact with $\alpha 2\delta-1$

(A) Array tomography analysis of synaptic localization of $\alpha 2\delta-1$ in cerebral cortex. RGCs were immunostained for synapsin I (blue) and MAGUK (green). $\alpha 2\delta-1$ puncta (red) associate both with synapses (white circles) and with isolated presynaptic (diamonds) or postsynaptic (squares) puncta. The scale bar represents 2 μ m.

(B) Western-blot analysis of $\alpha 2\delta-1$ on the immunoprecipitation (IP) fractions performed with antibodies specific to TSP1, 2, or 4 as well as calcium channel $\alpha 1C$ (Cav1.2), or Agrin (positive and negative controls for IP, respectively).

(C) Western blot analysis of $\alpha 2\delta-1$ interaction with the synaptogenic domain of TSP2 (SD2). Left, HEK293 cell lysates from nontransfected (1), $\alpha 2\delta-1$ -FLAG alone (2), SD2 alone (3), $\alpha 2\delta-1$ -FLAG and SD2 (4), and $\alpha 1\delta-1$ -FLAG and Control-myc-His construct (5) transfected cells. SD2 and Control-his-myc protein are marked with red \bullet . Anti-his antibody cross-reacts with several histidine rich proteins in HEK293 cell lysates (marked with a blue $*$). Anti- $\alpha 2\delta-1$ antibody also weakly recognizes the human $\alpha 2\delta-1$ expressed endogenously in HEK293 cells at low levels (blue \blacklozenge) Right, anti-FLAG IP fractions from $\alpha 2\delta-1$ -FLAG alone (6), SD2 alone (7), $\alpha 2\delta-1$ -FLAG and SD2 (8), and $\alpha 2\delta-1$ -FLAG and Control-myc-His construct (9) transfections.

(D) Domain structure of $\alpha 2\delta-1$ protein and scheme of $\alpha 2\delta-1$ protein C (PC) tagged constructs. SP, signal peptide; vWA_N and VGCC_ $\alpha 2$, putative domains of unknown structure. Yellow boxes indicate putative helical regions where no domain has yet been predicted. The red box shows the transmembrane (TM) region. Orange hexagons indicate predicted N-glycosylation sites, and purple bars indicate positions of cysteines.

(E) SD2 interacts with the VWF-A domain of $\alpha 2\delta-1$. Lane 1 is nontransfected HEK293 cell lysate. SD2 was coexpressed with PC tagged full-length $\alpha 2\delta-1$, $\alpha 2$ only, or VWF-A only constructs (lanes 3, 4, and 5) as well as CXCR4. SD2 coimmunoprecipitated with the $\alpha 2$ only (8) and VWF-A only (9) constructs of $\alpha 2\delta-1$ as well as the full-length protein (7) with anti-PC beads, (red arrows). SD2 did not copurify with CXCR4 (6).




Figure 4. $\alpha 2\delta-1$ Is the TSP Receptor Involved in Synaptogenesis

(A) RGCs were transfected with empty vector (pcDNA3, Invitrogen) or pcDNA3 constructs that express full-length $\alpha 2\delta-1$, $\delta-1$ only, or $\alpha 2\delta-1$ -Adh. The synapses received by transfected cells (marked by GFP coexpression) were then quantified. $n = 20$ cells. Error bars show the mean \pm SEM, $*p < 0.05$.

(B) Quantification of the effects of monoclonal antibodies 5A5 and 3B4 (mouse monoclonals raised against the VWF-A domain of $\alpha 2\delta-1$; Mazorx, Inc.) and anti-Thy1 antibody OX7 in synapse formation. 5A5 and 3B7 mimic TSP's synaptogenic function. $n = 30$ cells. Error bars show the mean \pm SEM, $*p < 0.05$.

(C) Western blot analysis of cell lysates from HEK293 cells, which were cotransfected with an expression vector for rat $\alpha 2\delta-1$ and siControl or si $\alpha 2\delta-1$ pools, with a monoclonal antibody against $\alpha 2\delta-1$ or against β -actin.

(D) Immunostaining of siRNA-transfected RGCs (marked blue by GFP coexpression) for colocalization of synaptotagmin (red) and PSD-95 (green). RGCs that were transfected with si $\alpha 2\delta-1$ did not form many synapses even in the presence of astrocytes (see inset i versus ii). The scale bar represents 30 μ m.

(E) Quantification of the effects of siRNA pools on astrocyte and TSP-induced synapse formation in RGCs. $n = 20$ cells. Error bars show the mean \pm SEM, $*p < 0.05$.

(F) Overexpression of human $\alpha 2\delta-1$, which is resistant to si $\alpha 2\delta-1$ (9), rescues the inhibition of SD2-induced synapse formation by si $\alpha 2\delta-1$ (9). $n = 20$ cells. Error bars show the mean \pm SEM, $*p < 0.05$.

blocks synaptogenesis via specific inhibition of rat $\alpha 2\delta-1$ messenger RNA (mRNA). Taken together, these results demonstrate that $\alpha 2\delta-1$ is necessary for TSP and astrocyte-induced

synapse formation in vitro. Since we analyze the effect of $\alpha 2\delta-1$ overexpression and knockdown in the postsynaptic cells receiving synapses, these data show a postsynaptic sufficiency




Figure 5. $\alpha 2\delta$ -1 Overexpression In Vivo Increases Excitatory Synapse Number

(A) Immunolabeling of cortices from littermate wild-type (WT) and $\alpha 2\delta$ -1-overexpressing transgenic (TG) P21 mice for VGLut2 and PSD95. The number of colocalized VGLut2/PSD95 puncta (white arrows in insets i and ii) was higher in the TGs than the WT. The scale bar represents 20 μ m.

(B) Quantification of VGLut2/PSD95 colocalization in brain sections from WT and TG mice. Error bars show the mean \pm SEM, * $p < 0.05$.

(C) Representative raw data traces of mEPSCs from layer IV cortical pyramidal neurons recorded from a WT and an $\alpha 2\delta$ -1 TG mouse. Top, condensed trace. Bottom, expanded trace.

(D) Summary of the frequency of mEPSCs in layer IV cortical pyramidal neurons of $\alpha 2\delta$ -1 TG and WT. TG = 3.5 ± 0.3 Hz ($n = 11$ cells); WT = 2.1 ± 0.2 Hz ($n = 12$ cells). Error bars show the mean Hz \pm SEM, $p = 0.002$.

(E) Summary of the amplitude of mEPSCs in layer IV cortical pyramidal neurons of $\alpha 2\delta$ -1 TG and WT. TG = 11.9 ± 0.3 pA, WT = 11.6 ± 0.3 pA. Error bars show the mean \pm SEM, $p = 0.5$.

and necessity for $\alpha 2\delta$ -1 in astrocyte/TSP-induced synapse formation.

$\alpha 2\delta$ -1-Mediated Synapse Formation Does Not Depend on Calcium Channel Surface Level or Function

$\alpha 2\delta$ -1 is known to enhance calcium channel function and trafficking (Arikath and Campbell, 2003). We therefore investigated whether the activity of $\alpha 2\delta$ -1 in synapse formation is linked to its role in increasing calcium currents or calcium channel levels. Gene expression analysis of RGCs show that these cells express predominantly postsynaptic L-type and presynaptic N- and P/Q-type voltage gated calcium channels (VGCCs). To directly test whether VGCC function was required for astrocyte-induced synapse formation, we added L-type calcium channel blockers to RGCs to block L-type channel function. These drugs had no effect on SD2-induced synapse formation (Figure S5A). Similarly presynaptic N- and P/Q-type channel blockers did not block

TSP-induced synapse formation (data not shown). We next investigated whether increase of postsynaptic L-type calcium channel expression in RGCs would enhance synapse formation. Overexpression of L-type $\alpha 1C$ and β subunits in RGCs had no effect on astrocyte-induced synapse formation (Figure S5B). Finally, we tested whether TSP treatment would lead to an increase in cytoplasmic calcium levels in RGCs. Neither acute nor long-term TSP treatment led to a noticeable rise in spontaneous calcium oscillations in RGCs (Figure S6). Taken together, these results show that the role of $\alpha 2\delta$ -1 in synapse formation cannot be directly linked to calcium channel expression levels or function.

Overexpression of $\alpha 2\delta$ -1 in Neurons Enhances Synapse Formation In Vivo

To determine whether $\alpha 2\delta$ -1 plays a role in synapse formation in vivo, we examined synapse number and synaptic activity in transgenic mice that selectively overexpress $\alpha 2\delta$ -1 in CNS neurons, under the control of the Thy1 promoter (Li et al., 2006). Sagittal brain sections from 21-day-old (P21) transgenic (TG) and wild-type (WT) littermate mice were coimmunostained for PSD95 and either the presynaptic vesicular glutamate transporter 1 or 2 (VGLut1 and VGLut2). We quantified the number of colocalized pre- and postsynaptic puncta to determine the synaptic density in the cortices of these mice. The TG mice had significantly higher numbers of VGLut2-positive excitatory synapses in the cortex than did the littermate WT controls (1.8-fold, Figures 5A and 5B); however, there was no difference in the number of VGLut1-positive synapses between WT and TG mice (Figures S7A and S7B). The observation that $\alpha 2\delta$ -1 overexpression increases VGLut2-positive synapses provides evidence that excitatory synapse formation is enhanced in the TGs.

In the adult cortex thalamic neurons projecting onto layer IV neurons form VGLut2-positive synapses, while synapses made

between cortical neurons contain VGlut1 (Freneau et al., 2004). We confirmed that the increase in VGlut2-positive synapse number was not due to an increase in the number of neurons in the cortex or thalamus, as the number of cells and neurons in WT and TG brains were identical in these brain regions (Figures S8A and S8B).

Excitatory synapses in the cortex are initially formed as VGlut2 positive, and there is an isoform switch to VGlut1 that happens around the second week of postnatal development (Miyazaki et al., 2003). During this period, some synapses can transiently be both VGlut1 and 2 positive (Nakamura et al., 2005). We determined that the increase in VGlut2-positive synapses was not due to a prolonged colocalization of VGlut1 and 2 at the same synapse, since these proteins seldom colocalized at P21, and there were no differences in the frequency of colocalization of these proteins between genotypes (Figures S9A and S9B). Taken together, these results show that the increase in VGlut2-positive synapses associated with $\alpha 2\delta$ -1 overexpression is due to neither an increase in the number of cortical or thalamic neurons nor a delay in the isoform switch from VGlut2 to 1 in the cortex.

In addition to analyzing synapse number by immunohistochemistry, we performed whole-cell patch-clamp recordings in layer IV cortical pyramidal neurons and assayed the number of active synapses by analyzing the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs). Recorded cells were dye filled, and their identity was verified (Figures S10A and S10B). We targeted layer IV pyramidal neurons both because these cells receive VGlut2-positive synapses and because array tomography revealed an increase in $\alpha 2\delta$ -1 immunostaining in TG animals in this layer (Figure S10C). There was a highly significant increase in the frequency of mEPSCs in $\alpha 2\delta$ -1 TG mice compared with WT mice (1.63-fold), with no effect on the amplitude of mEPSCs (Figures 5C–5E). The increase in the frequency of mEPSCs in TG mice is very consistent with the increased excitatory synapse number found by the immunohistochemical analysis described above. Taken together, these data show that $\alpha 2\delta$ -1 plays a role in promoting excitatory synapse formation in the brain.

Gabapentin, the High-Affinity Ligand for $\alpha 2\delta$ -1, Strongly Inhibits TSP-Induced Synapse Formation

In order to determine whether GBP, the high-affinity ligand for $\alpha 2\delta$ -1 affects TSP or astrocyte-induced synapse formation, we cultured RGCs with TSP, SD2, or ACM in the presence or absence of GBP (32 μ M). GBP strongly inhibited TSP, SD2, or astrocyte-induced synapse formation (Figures 6A–6C and S1C). To determine whether GBP could dissolve already established synapses, we cultured RGCs with SD2 for 5 days to allow synapses to form and then added GBP for an additional day. GBP had no effect on synapse number when added after the synapses were formed (Figure 6C). Thus, GBP blocks new synapse formation induced by TSP and astrocytes but does not dissolve established synapses. Interestingly, GABA, an inhibitory neurotransmitter that binds to $\alpha 2\delta$ -1 with much lower affinity (IC_{50} = 650 μ M) (Suman-Chauhan et al., 1993), also blocked SD2-induced synapse formation when used at high concentrations (Figure S11).

To determine whether GBP blocks TSP-induced synapse formation by inhibiting the $\alpha 2\delta$ -1-TSP interaction, we cocultured two populations of HEK293 cells, one expressing $\alpha 2\delta$ -1FLAG and the other expressing SD2, in the presence or absence of GBP. Immunoprecipitation with anti-FLAG antibodies revealed that the SD2- $\alpha 2\delta$ -1 interaction was diminished in the presence of GBP (Figure 6D), suggesting that GBP blocks TSP-induced synapse formation by interfering with the interaction between $\alpha 2\delta$ -1 and TSP.

To test whether GBP similarly blocks synapse formation *in vivo*, we injected neonatal mice with either GBP or saline for the first postnatal week, which coincides with the initiation of synapse formation in the brain. At this age, glutamatergic synapses in the cortex are predominantly VGlut2 positive (Miyazaki et al., 2003). Therefore, we coimmunostained sagittal brain sections from P7 saline- or GBP-injected mice with antibodies against VGlut2 and PSD95 and quantified the number of colocalized pre- and postsynaptic puncta in the cortex of these mice. There were significantly fewer excitatory synapses in the cerebral cortex of the GBP-injected mice relative to control mice (Figure 6E). This difference was mainly due to a severe decrease in synapse number in half of the GBP-injected animals. In the mice that responded strongly to GBP, the VGlut2/PSD95 synaptic densities went down profoundly, to less than 10% of the saline-injected values, although the number of neurons did not change. GBP injection affected both VGlut2 and PSD95 puncta by reducing their number, size, and colocalization (Figure 6E), similar to its effect on synaptic puncta *in vitro*. These findings show that GBP is a powerful inhibitor of new synapse formation both *in vitro* and *in vivo*.

Inhibition of TSP-Induced Synapse Formation Interferes with Lesion-Induced Barrel Cortex Plasticity

To determine whether astrocyte-induced synapse formation is involved in remodeling neural circuits during development, we utilized a well-established developmental plasticity paradigm, the “barrel cortex plasticity” assay. The nerves that innervate the major whiskers on the snout of the mouse project to the brain as a topographically ordered “somatotopic” map (Erzurumlu et al., 2006). In the primary somatosensory cortex, this map is organized as “barrels” (Figure 7A) that exhibit structural changes in response to peripheral whisker manipulations.

To test whether TSP-induced synapse formation is involved in mechanisms of experience-dependent plasticity, we injected two groups of neonatal mice either with GBP or saline daily starting at P0 until P7. On P1, five whiskers from the C row on one side of each mouse were lesioned. The mice were sacrificed at P7, and barrel cortex organization in both the unlesioned “control” and the lesioned hemisphere was analyzed. Both saline- and GBP-injected mice had typical barrel organization formed on the control side (Figure 7B, top two left panels). On the lesioned side, although all saline-injected mice displayed a normal barrel cortex plasticity pattern, 50% of the GBP-injected mice displayed an atypical plasticity response (Figure 7B, right panels), where the A and B rows as well as the C row lost form and fused, even though the whisker follicles for these rows were undisturbed in all mice (Figures 7B, 7C, and S12).




Figure 6. Gabapentin Inhibits TSP/Astrocyte-Induced Synapse Formation

(A) Immunostaining for synaptotagmin (red) and PSD-95 (green) in RGCs treated with SD2 in the presence or absence of GBP. The scale bar represents 30 μ m. (B and C) Quantification of the effect of GBP on astrocyte- or TSP-induced synapse formation (B) and on SD2-induced synapse formation (C). GBP blocks SD2's synaptogenic effect when added simultaneously with SD2 but not when added after synapses have formed. $n = 20$ cells. Error bars show the mean \pm SEM, * $p < 0.05$. (D) Western Blot analysis of effect of GBP on the SD2- $\alpha 2\delta$ -1 interaction. Red arrows point to SD2 protein coimmunoprecipitated with $\alpha 2\delta$ -1FLAG. Anti- $\alpha 2\delta$ -1 antibody also recognizes weakly expressed endogenous human $\alpha 2\delta$ -1 expressed by HEK293 cells (lanes 2 and 5, top blots). (E) Quantification of colocalization of VGlut2 and PSD95 in brain sections from saline- and GBP-injected P7 mice. Error bars show the mean \pm SEM, * $p < 0.05$. (F) Immunolabeling of saline- and GBP-injected P7 cortices for VGlut2 (green) and PSD95 (red). Half of GBP-injected mice had a very strong reduction in the number, size, and colocalization of synaptic puncta (white arrows, inset i versus ii). Scale bars represent 20 μ m.

To more directly test the role of TSPs, we examined barrel cortex plasticity in *TSP1/2* double-null (KO) mice. A third of the *TSP1/2* KO mice we analyzed showed a very similar, aberrant barrel cortex plasticity phenotype (Figure 7B, bottom right), a pattern that we

never observed in any of the WT mice. These findings suggest that astrocyte-secreted TSPs are required for rewiring of the barrels post injury and that the main effect of GBP in barrel cortex plasticity is mediated by its inhibition of TSP-induced synapse formation.




Figure 7. TSP-Induced Synapse Formation Is Involved in Barrel Cortex Plasticity

(A) Schematic presentation of the experimental paradigm: ablation of the C row of whiskers at P1 causes corresponding reorganization of barrel representations at P7 in contralateral hemisphere.

(B) Immunolabeling of thalamocortical afferents to the barrel cortex with an antibody against 5HT transporter. The left images show control barrel cortex. The right images are representative examples of lesion-induced plasticity after whisker follicle ablation in mice that were injected with saline (top) or GBP (middle). The bottom row shows control (left) and lesioned (right) barrel cortices from a TSP1/2KO mouse. Arrows flank the C row of barrels corresponding to lesioned whiskers. Brackets and dashed lines show the expansion of D row barrels. Asterisks denote regions of abnormal lesion-induced plasticity.

(C) Hematoxylin staining of the whisker pads from mice whose barrels are shown in (B) showing selective ablation of C row follicles.

DISCUSSION

$\alpha 2\delta$ -1 Is a Neuronal Thrombospondin Receptor Responsible for Synaptogenesis

The molecular interactions that regulate initiation of synapse formation are not well characterized. Our finding that $\alpha 2\delta$ -1 is the TSP receptor required for synaptogenesis provides molecular insight into the mechanism of synapse formation and raises the question of how TSP- $\alpha 2\delta$ -1 interaction leads to initiation of synaptogenesis.

Our findings lead us to the following working model: $\alpha 2\delta$ -1 is the extracellular ligand-binding portion of a postsynaptic “synaptogenic signaling complex” (Figure S13) that regulates formation of an initial synaptic adhesion between a dendrite and an axon. TSP binding to the VWF-A domain of $\alpha 2\delta$ -1 causes a structural rearrangement in this molecule, which triggers subsequent conformational shifts in its binding partner(s) and switches this complex to an “active” state. $\alpha 2\delta$ -1 activation by TSP then leads to inter- and intracellular signaling events that trigger the recruitment of synaptic adhesion and scaffolding molecules to nascent synaptic sites. VWF-A domains are known protein-protein inter-

action domains that act as conformational switches and alter a protein’s structure upon binding to its ligand (Bork and Rohde, 1991; Whittaker and Hynes, 2002). The fact that antibodies directed against the VWF-A domain of $\alpha 2\delta$ -1 can mimic the synaptogenic function of TSP also suggests a binding-induced activation of $\alpha 2\delta$ -1 in synapse formation.

It is unlikely that $\alpha 2\delta$ -1 can induce intracellular signaling by itself since it has a very short cytoplasmic tail and the extracellular domain of $\alpha 2\delta$ -1 is able to mimic the full-length $\alpha 2\delta$ -1’s function in synapse formation. $\alpha 2\delta$ -1 may be linked to intracellular signaling mechanisms via other membrane proteins. A calcium channel $\alpha 1$ subunit can be a part of this complex. $\alpha 1$, after being recruited by $\alpha 2\delta$ -1 to dendrite-axon contact sites, could undergo conformational changes induced by TSP- $\alpha 2\delta$ -1 interaction and potentially serve as a platform for the nucleation of synaptic proteins at the new synaptic site (Figure S13).

$\alpha 2\delta$ -1 has previously been shown to enhance calcium currents and surface trafficking of calcium channel $\alpha 1$ subunits (Arikath and Campbell, 2003). Is $\alpha 2\delta$ -1’s role in synapse formation linked to this function? We have several observations that suggest otherwise. First, overexpression of $\alpha 2\delta$ -1 in the absence of

TSP enhances calcium channel surface expression (Gurnett et al., 1996) but does not lead to an increase in synapse number. Second, the $\alpha 2\delta$ -1Adh protein can mimic the effect of full-length $\alpha 2\delta$ -1 in enhancing synapse formation, but it does not induce an increase in calcium currents like the full-length protein (Gurnett et al., 1996). Third, neither the overexpression nor the pharmacological blocking of calcium channels interfered with TSP-induced synapse formation. Similarly, acute or long-term TSP treatment did not increase cytoplasmic calcium levels in RGCs; thus, it is unlikely that TSP triggers activation of a homeostatic mechanism that can activate synapse formation. Taken together, our results show that global changes in calcium channel numbers or currents are not involved in TSP-induced synapse formation. However, since the $\alpha 2\delta$ -1Adh construct, which enhances synapse formation, can interact with the $\alpha 1$ subunit, and since δ -1 construct, which inhibits synapse formation, can interfere with the $\alpha 2\delta$ -1 and $\alpha 1$ interaction, a physical interaction between $\alpha 2\delta$ -1 and the calcium channel $\alpha 1$ subunits might be important for synapse formation. Future studies exploring whether knocking down expression of $\alpha 1$ subunits affects TSP-induced synapse formation are necessary to verify this possibility.

$\alpha 2\delta$ -1 might also interact with other proteins that are involved in organization of synaptic contacts. Such dual functions have been described for the γ subunits of VGCCs also known as stargazins. They were initially isolated as a component of the calcium channel complex but are now known to play primary roles in AMPA receptor regulation (Chen et al., 2000). Identification of the relevant $\alpha 2\delta$ -1 interacting molecules promises to provide new molecular insight into the process of synapse formation. In addition, there could be other CNS molecules that share TSP's and GBP's abilities to bind to $\alpha 2\delta$ -1 and trigger or inhibit synapse formation.

Our findings have a number of important implications for future studies. First, TSP and $\alpha 2\delta$ -1 are also highly concentrated at the neuromuscular junction; thus, it is likely that these molecules are involved in formation of this synapse (Arber and Caroni, 1995; Arikath and Campbell, 2003). Second, other $\alpha 2\delta$ family members might also regulate synapse formation. In fact, disruption of the $\alpha 2\delta$ -4 gene in mice leads to a severe loss of ribbon synapses in the photoreceptor cells (Wycisk et al., 2006), and mutations in $\alpha 2\delta$ -3 cause defects in synaptic transmission and a morphological defect in presynaptic organization at the *Drosophila* neuromuscular junction (Dickman et al., 2008; Kurshan et al., 2009). These observations suggest that the function of $\alpha 2\delta$ subunits in promoting synaptogenesis may be evolutionarily conserved and can be exerted presynaptically as well as postsynaptically.

Gabapentin Is a Powerful Blocker of Synapse Formation

Our findings suggest that GBP blocks TSP-induced synapse formation by interfering with TSP- $\alpha 2\delta$ -1 interaction. GBP binding to $\alpha 2\delta$ -1 involves a region just upstream of the VWF-A domain in $\alpha 2$ (Wang et al., 1999). Therefore, it is unlikely that TSP and GBP compete for the same binding site. It is known for integrins that conformational changes in VWF-A domains can be constrained by interactions made by regions flanking this domain (Bork and Rohde, 1991; Whittaker and Hynes, 2002). We propose that GBP binding to $\alpha 2\delta$ -1 restricts the conformation of the VWF-A

domain and keeps $\alpha 2\delta$ -1 in its "inactive conformation." This perturbs the TSP- $\alpha 2\delta$ -1 interaction and inhibits activation of the synaptogenic signaling complex (Figure S13).

GABA, leucine, and isoleucine can also bind to $\alpha 2\delta$ -1, albeit at lower affinity than GBP (Dooley et al., 2007), and thus they can be physiological ligands for $\alpha 2\delta$ -1 and regulate excitatory synapse formation. In agreement with this, we found that high concentrations of GABA inhibited synapse formation in culture. Such high concentrations of GABA are present in the CNS right next to a GABAergic axon. Dendritic filopodia in the developing brain actively seek for synaptic partners and establish exclusively glutamatergic contacts. Interestingly, dendritic filopodia that contact a GABAergic axon never stabilize the contact and retract (Lohmann and Bonhoeffer, 2008; Wierenga et al., 2008). In future studies, it will be interesting to explore whether $\alpha 2\delta$ -1 functions as a physiologically relevant GABA receptor that enables initial selectivity for the formation of excitatory synapses by dendritic filopodia.

$\alpha 2\delta$ -1-TSP Interaction Regulates Synapse Formation during Development and after Injury

The ability of GBP to strongly decrease synapse formation in wild-type mouse brains points to a critical role for TSP- $\alpha 2\delta$ -1 interaction and astrocytes in driving synaptogenesis in vivo. In addition, the correct execution of barrel cortex plasticity depends on TSP-induced synapse formation. Since the unlesioned barrel cortices are formed normally both in GBP injected and *TSP1/2* KO mice, TSPs might specifically play a role in synaptic remodeling plasticity upon injury in this system. These findings add to the growing data that astrocytes not only actively contribute to normal synaptogenesis but also mediate synaptic remodeling events after injury.

It is interesting that the effect of GBP in vivo is an "all or none" effect rather than a fractional decrease in synapse number, and only 50% of the mice responded strongly to GBP injections. It is possible that a critical threshold concentration of GBP in the cerebrospinal fluid is required to be effective in blocking synapse formation, which is only achieved in half of the mice. Gender could be critical in GBP responsiveness by affecting in GBP delivery to neural tissues and can explain the 50% penetrance we have observed. In fact, a recent study demonstrated that intraperitoneal GBP injections were not as effective at blocking seizures in female mice as in males (Traa et al., 2008).

Since GBP strongly blocks TSP-induced synapse formation within its therapeutic concentration, it is possible that inhibition of excitatory synapse formation is an important mode of its therapeutic action in epilepsy and pain. Reactive astrocytosis is prominent both in epileptic lesions and in the spinal cord after peripheral nerve injury that leads to neuropathic pain (Liu et al., 2000; Ridet et al., 1997). Reactive astrocytes express high levels of TSP1 and 2 (Lin et al., 2003). Similarly, upon injury in the spinal nerve, both $\alpha 2\delta$ -1 and TSP4 genes are upregulated in the spinal cord (Valder et al., 2003; Wang et al., 2002). Increased $\alpha 2\delta$ -1 levels were shown to lead to enhanced excitatory synaptic transmission and elevated neuropathic pain states (Li et al., 2004, 2006). Similarly, there is increased excitation in the epileptic brain (Prince, 1999). All these observations point to the possibility that aberrant excitatory synaptogenesis may contribute to

the pathophysiology of neuropathic pain and epilepsy. Thus GBP may act by limiting these excess synapses from forming, a possibility which can now be directly tested in animal models of these diseases. In conclusion, by identifying $\alpha 2\delta$ -1 as a receptor for TSP mediated glial-induced synapse formation, we have gained molecular understanding not only of astrocytes' role in synapse formation in health and disease, but also of the process of synapse formation itself.

EXPERIMENTAL PROCEDURES

Purification and Culture of RGCs and Astrocytes

RGCs were purified with greater than 99.5% purity from P5 Sprague-Dawley rats (Charles Rivers) and cultured in serum-free medium as previously described (Christopherson et al., 2005; Meyer-Franke et al., 1995; Ullian et al., 2001). Cortical astrocyte inserts and ACM were prepared as described in (Christopherson et al., 2005). RGCs were cultured for 3–4 days to allow robust process outgrowth and then cultured with astrocyte inserts, ACM, or TSPs for an additional 6 days.

Mice

TSP1/2 double-null mice on an FVB background were used ($n = 12$). WT FVB mice were purchased from Charles River Laboratories. Brains from P21, $\alpha 2\delta$ -1-overexpressing, TG mice and their littermate WT controls ($n = 8$) were provided by Li and colleagues and are described in Li et al. (2006).

Quantification of Synapse Numbers

For synapse quantification of RGCs, we followed a previously developed immunohistochemistry (IHC)-based method described and validated in Christopherson et al. (2005) and Ullian et al. (2001). For quantification of excitatory synapse number in mouse brain, three sagittal brain sections per animal were stained with pre- and postsynaptic markers, and 5 μm confocal scans were performed (optical section width 0.38 μm , 14 optical sections each) at the cortex. The parameters for scanning were always set up for WT (or saline-injected) brain sections, and the same imaging parameters were used for TG (or GBP-injected) animals. Merged single optical section images at 1 μm intervals were analyzed with the ImageJ puncta analyzer option to count for number of colocalized pre- and postsynaptic puncta (five optical sections/section, 15 images/brain). Average synaptic density per imaged area was calculated for each condition. Details on IHC conditions, image acquisition, and quantification can be found in Supplemental Data.

Electrophysiological Recordings

Experiments were carried out on littermate WT and $\alpha 2\delta$ -1 transgenic mice aged P21–P25, and recordings and analysis were both carried out blind to genotype. Whole-cell voltage-clamp recordings of layer IV pyramidal neurons in the visual cortex were carried out at room temperature in flowing isotonic saline containing 1 μM tetrodotoxin (TTX) and 40 μM bicuculline to isolate mEPSCs. mEPSCs were recorded for one minute and analyzed with MiniAnalysis software from Synaptosoft.

Saline and Gabapentin Injections

Mice were given daily intraperitoneal injections of either a single dose of 400 mg/kg of GBP (Sigma-Aldrich) or a matching volume of saline solution (PBS). Pups were weighed just before injections to determine the dose administered and to follow weight gain and general health, which showed no differences between GBP- and saline-injected mice.

Whisker Lesions and Barrel Cortex Immunohistochemistry

Neonatal mice were held on their left side under a dissecting scope and received two parallel incisions with a surgical blade flanking the C row of whiskers to be removed. The skin between the incisions was pulled back with forceps. Follicles were individually removed with forceps at the opening. The lesion site was then cauterized with silver nitrate using flexible caustic applicators (Tech-Med). Mice were allowed to recover in their home cage.

P7 mice were sacrificed, and brains were harvested. Samples were blinded during rest of the analysis of the barrel cortex plasticity. Tangential cortical sections were stained with anti-serotonin (5-HT) transporter rabbit polyclonal antibody (Calbiochem, 1:400). Barrels were imaged with a Nikon Eclipse E800 fluorescent microscope, and images were digitally acquired with an SPOT camera (Diagnostic Instruments). The complete maps of the barrel cortex were reassembled from 5-HT-stained images of serial sections by reconstruction in Photoshop (Adobe Systems). Details on the immunohistochemistry conditions, image acquisition, and data analysis can be found in Supplemental Data.

SUPPLEMENTAL DATA

Supplemental Data include Supplemental Experimental Procedures and 13 figures and can be found with this article online at [http://www.cell.com/supplemental/S0092-8674\(09\)01185-4](http://www.cell.com/supplemental/S0092-8674(09)01185-4).

ACKNOWLEDGMENTS

We thank Maria L. Fabian, Navid Nouri, and Mark Duquette for excellent technical assistance, and Beth Stevens, Junryo Watanabe, and Alissa Winzeler for critical reading of the manuscript. This work was supported by grants from the National Institute of Drug Addiction (DA15043 to B.A.B.), the National Heart, Lung and Blood Institute (HL49081 to J.L.), and the National Institute of Neurological Disorders and Stroke and National Institute of Dental and Craniofacial Research (NS40135 and DE14545 to Z.D.L.). C.E. and N.J.A. were supported by the Human Frontiers Scientific Program long-term fellowships and A.D.H. by the Helen Hay Whitney postdoctoral fellowship. Arnon Rosenthal is founder and president of MazoRx Inc.

Received: February 16, 2008

Revised: February 4, 2009

Accepted: August 26, 2009

Published online: October 8, 2009

REFERENCES

- Adams, J.C., and Lawler, J. (2004). The thrombospondins. *Int. J. Biochem. Cell Biol.* 36, 961–968.
- Annis, D.S., Murphy-Ullrich, J.E., and Mosher, D.F. (2006). Function-blocking antithrombospondin-1 monoclonal antibodies. *J. Thromb. Haemost.* 4, 459–468.
- Annis, D.S., Gunderson, K.A., and Mosher, D.F. (2007). Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. *J. Biol. Chem.* 282, 27067–27075.
- Arber, S., and Caroni, P. (1995). Thrombospondin-4, an extracellular matrix protein expressed in the developing and adult nervous system promotes neurite outgrowth. *J. Cell Biol.* 131, 1083–1094.
- Arikath, J., and Campbell, K.P. (2003). Auxiliary subunits: essential components of the voltage-gated calcium channel complex. *Curr. Opin. Neurobiol.* 13, 298–307.
- Bork, P., and Rohde, K. (1991). More von Willebrand factor type A domains? Sequence similarities with malaria thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor. *Biochem. J.* 279, 908–910.
- Bornstein, P., Agah, A., and Kyriakides, T.R. (2004). The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. *Int. J. Biochem. Cell Biol.* 36, 1115–1125.
- Carlson, C.B., Lawler, J., and Mosher, D.F. (2008). Structures of thrombospondins. *Cell. Mol. Life Sci.* 65, 672–686.
- Chen, L., Chetkovich, D.M., Petralia, R.S., Sweeney, N.T., Kawasaki, Y., Wenthold, R.J., Bredt, D.S., and Nicoll, R.A. (2000). Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. *Nature* 408, 936–943.

- Christopherson, K.S., Ullian, E.M., Stokes, C.C., Mullaney, C.E., Hell, J.W., Agah, A., Lawler, J., Mosher, D.F., Bornstein, P., and Barres, B.A. (2005). Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. *Cell* 120, 421–433.
- Cole, R.L., Lechner, S.M., Williams, M.E., Prodanovich, P., Bleicher, L., Varney, M.A., and Gu, G. (2005). Differential distribution of voltage-gated calcium channel alpha-2 delta (alpha2delta) subunit mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. *J. Comp. Neurol.* 491, 246–269.
- Davies, A., Hendrich, J., Van Minh, A.T., Wratten, J., Douglas, L., and Dolphin, A.C. (2007). Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. *Trends Pharmacol. Sci.* 28, 220–228.
- Dickman, D.K., Kurshan, P.T., and Schwarz, T.L. (2008). Mutations in a *Drosophila* alpha2delta voltage-gated calcium channel subunit reveal a crucial synaptic function. *J. Neurosci.* 28, 31–38.
- Dooley, D.J., Taylor, C.P., Donevan, S., and Feltner, D. (2007). Ca²⁺ channel alpha2delta ligands: novel modulators of neurotransmission. *Trends Pharmacol. Sci.* 28, 75–82.
- Eroglu, C., Barres, B.A., and Stevens, B. (2008). Glia as active participants in the development and function of synapses. In *Structural and Functional Organization of the Synapse*, J. Hell and M. Ehlers, eds. (New York: Springer), pp. 683–714.
- Erzurumlu, R.S., Chen, Z.F., and Jacquin, M.F. (2006). Molecular determinants of the face map development in the trigeminal brainstem. *Anat. Rec.* 288, 121–134.
- Field, M.J., Cox, P.J., Stott, E., Melrose, H., Offord, J., Su, T.Z., Bramwell, S., Corradini, L., England, S., Winks, J., et al. (2006). Identification of the alpha2delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. *Proc. Natl. Acad. Sci. USA* 103, 17537–17542.
- Fox, M.A., and Umemori, H. (2006). Seeking long-term relationship: axon and target communicate to organize synaptic differentiation. *J. Neurochem.* 97, 1215–1231.
- Freneau, R.T., Jr., Voglmaier, S., Seal, R.P., and Edwards, R.H. (2004). VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. *Trends Neurosci.* 27, 98–103.
- Garcia, K., Nabhani, T., and Garcia, J. (2007). The calcium channel alpha2/delta1 subunit is involved in extracellular signaling. *J. Physiol.* 586, 727–738.
- Gee, N.S., Brown, J.P., Dissanayake, V.U., Offord, J., Thurlow, R., and Woodruff, G.N. (1996). The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. *J. Biol. Chem.* 271, 5768–5776.
- Gurnett, C.A., De Waard, M., and Campbell, K.P. (1996). Dual function of the voltage-dependent Ca²⁺ channel alpha 2 delta subunit in current stimulation and subunit interaction. *Neuron* 16, 431–440.
- Kaltenbach, L.S., Romero, E., Becklin, R.R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., Hurlburt, A., et al. (2007). Huntingtin interacting proteins are genetic modifiers of neurodegeneration. *PLoS Genet.* 3, e82.
- Klugbauer, N., Marais, E., and Hofmann, F. (2003). Calcium channel alpha2delta subunits: differential expression, function, and drug binding. *J. Bioenerg. Biomembr.* 35, 639–647.
- Kurshan, P.T., Matos, A.O., and Schwarz, T.L. (2009). The presynaptic Ca²⁺-channel subunit! 2''-3 is required for synaptic morphogenesis independent of its Ca²⁺-channel functions. *Nat. Neurosci.* 12, in press. 10.1038/nn.2417.
- Li, C.Y., Song, Y.H., Higuera, E.S., and Luo, Z.D. (2004). Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. *J. Neurosci.* 24, 8494–8499.
- Li, C.Y., Zhang, X.L., Matthews, E.A., Li, K.W., Kurwa, A., Boroujerdi, A., Gross, J., Gold, M.S., Dickenson, A.H., Feng, G., et al. (2006). Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. *Pain* 125, 20–34.
- Liauw, J., Hoang, S., Choi, M., Eroglu, C., Choi, M., Sun, G.H., Percy, M., Wildman-Tobriner, B., Bliss, T., Guzman, R.G., et al. (2008). Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke. *J. Cereb. Blood Flow Metab.* 28, 1722–1732.
- Lin, T.N., Kim, G.M., Chen, J.J., Cheung, W.M., He, Y.Y., and Hsu, C.Y. (2003). Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. *Stroke* 34, 177–186.
- Liu, L., Rudin, M., and Kozlova, E.N. (2000). Glial cell proliferation in the spinal cord after dorsal rhizotomy or sciatic nerve transection in the adult rat. *Exp. Brain Res.* 131, 64–73.
- Lohmann, C., and Bonhoeffer, T. (2008). A role for local calcium signaling in rapid synaptic partner selection by dendritic filopodia. *Neuron* 59, 253–260.
- Meyer-Franke, A., Kaplan, M.R., Pfrieger, F.W., and Barres, B.A. (1995). Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. *Neuron* 15, 805–819.
- Micheva, K.D., and Smith, S.J. (2007). Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits. *Neuron* 55, 25–36.
- Miyazaki, T., Fukaya, M., Shimizu, H., and Watanabe, M. (2003). Subtype switching of vesicular glutamate transporters at parallel fibre-Purkinje cell synapses in developing mouse cerebellum. *Eur. J. Neurosci.* 17, 2563–2572.
- Nakamura, K., Hioki, H., Fujiyama, F., and Kaneko, T. (2005). Postnatal changes of vesicular glutamate transporter (VGLUT)1 and VGLUT2 immunoreactivities and their colocalization in the mouse forebrain. *J. Comp. Neurol.* 492, 263–288.
- Pluskota, E., Stenina, O.I., Krukovets, I., Szpak, D., Topol, E.J., and Plow, E.F. (2005). Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. *Blood* 106, 3970–3978.
- Prince, D.A. (1999). Epileptogenic neurons and circuits. *Adv. Neurol.* 79, 665–684.
- Ridet, J.L., Malhotra, S.K., Privat, A., and Gage, F.H. (1997). Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci.* 20, 570–577.
- Suman-Chauhan, N., Webdale, L., Hill, D.R., and Woodruff, G.N. (1993). Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. *Eur. J. Pharmacol.* 244, 293–301.
- Traa, B.S., Mulholland, J.D., Kadam, S.D., Johnston, M.V., and Comi, A.M. (2008). Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. *Pediatr. Res.* 64, 81–85.
- Ullian, E.M., Sapperstein, S.K., Christopherson, K.S., and Barres, B.A. (2001). Control of synapse number by glia. *Science* 291, 657–661.
- Valder, C.R., Liu, J.J., Song, Y.H., and Luo, Z.D. (2003). Coupling gene chip analyses and rat genetic variances in identifying potential target genes that may contribute to neuropathic allodynia development. *J. Neurochem.* 87, 560–573.
- Wang, H., Sun, H., Della Penna, K., Benz, R.J., Xu, J., Gerhold, D.L., Holder, D.J., and Koblan, K.S. (2002). Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. *Neuroscience* 114, 529–546.
- Wang, M., Offord, J., Oxender, D.L., and Su, T.Z. (1999). Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding. *Biochem. J.* 342, 313–320.
- Whittaker, C.A., and Hynes, R.O. (2002). Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. *Mol. Biol. Cell* 13, 3369–3387.
- Wierenga, C.J., Becker, N., and Bonhoeffer, T. (2008). GABAergic synapses are formed without the involvement of dendritic protrusions. *Nat. Neurosci.* 11, 1044–1052.
- Wilkins, J.A., Li, A., Ni, H., Stupack, D.G., and Shen, C. (1996). Control of beta1 integrin function. Localization of stimulatory epitopes. *J. Biol. Chem.* 271, 3046–3051.
- Wycisk, K.A., Budde, B., Feil, S., Skosyrski, S., Buzzi, F., Neidhardt, J., Glaus, E., Nurnberg, P., Ruether, K., and Berger, W. (2006). Structural and functional abnormalities of retinal ribbon synapses due to *Cacna2d4* mutation. *Invest. Ophthalmol. Vis. Sci.* 47, 3523–3530.